J Caga1,2, M R Turner3, S Hsieh1, R M Ahmed4, E Devenney4, E Ramsey1, M C Zoing1, E Mioshi5, M C Kiernan1,2. 1. Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia. 2. Sydney Medical School, University of Sydney, Camperdown, NSW, Australia. 3. Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK. 4. Neuroscience Research Australia, Randwick, NSW, Australia. 5. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
Abstract
BACKGROUND AND PURPOSE: Apathy is the most commonly reported behavioural change in amyotrophic lateral sclerosis (ALS). However, the degree to which it affects prognosis and overlaps with depression in this population is unknown. The present study examined the relationship between level of apathy, mortality and survival time and whether apathy was linked to specific symptom clusters of depression. METHODS: A cohort of 76 consecutive ALS patients attending specialized multidisciplinary clinics were classified according to level of apathy. The effects of clinical factors and apathy on survival time were analysed using univariate and multivariate methods. RESULTS: The majority of patients with moderate to severe apathy died during the study (P = 0.003) and had a median survival time of 21.7 months, considerably shorter than patients with mild apathy (46.9 months) and no apathy (51.9 months) (P = 0.0001). Apathy remained a significant predictor of survival even after controlling for clinical factors and symptom duration at the time of study entry (hazard ratio 3.8, 95% confidence interval 1.9-7.5, P = 0.0001). Depression with demoralization was not associated with level of apathy (P = 0.172) whereas depression with anhedonia was more common in patients with apathy than in those without apathy (P = 0.006). CONCLUSIONS: The presence of severe apathy is an independent, negative prognostic factor in ALS.
BACKGROUND AND PURPOSE: Apathy is the most commonly reported behavioural change in amyotrophic lateral sclerosis (ALS). However, the degree to which it affects prognosis and overlaps with depression in this population is unknown. The present study examined the relationship between level of apathy, mortality and survival time and whether apathy was linked to specific symptom clusters of depression. METHODS: A cohort of 76 consecutive ALSpatients attending specialized multidisciplinary clinics were classified according to level of apathy. The effects of clinical factors and apathy on survival time were analysed using univariate and multivariate methods. RESULTS: The majority of patients with moderate to severe apathy died during the study (P = 0.003) and had a median survival time of 21.7 months, considerably shorter than patients with mild apathy (46.9 months) and no apathy (51.9 months) (P = 0.0001). Apathy remained a significant predictor of survival even after controlling for clinical factors and symptom duration at the time of study entry (hazard ratio 3.8, 95% confidence interval 1.9-7.5, P = 0.0001). Depression with demoralization was not associated with level of apathy (P = 0.172) whereas depression with anhedonia was more common in patients with apathy than in those without apathy (P = 0.006). CONCLUSIONS: The presence of severe apathy is an independent, negative prognostic factor in ALS.
Authors: J Caga; S Hsieh; E Highton-Williamson; M C Zoing; E Ramsey; E Devenney; R M Ahmed; M C Kiernan Journal: J Neurol Date: 2017-11-30 Impact factor: 4.849
Authors: Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2017-01-05 Impact factor: 4.092
Authors: Natasha E Garcia-Willingham; Abbey R Roach; Edward J Kasarskis; Suzanne C Segerstrom Journal: Psychosom Med Date: 2018-09 Impact factor: 4.312
Authors: Susan Woolley; Ray Goetz; Pam Factor-Litvak; Jennifer Murphy; Jonathan Hupf; Diana C Garofalo; Catherine Lomen-Hoerth; Howard Andrews; Daragh Heitzman; Richard Bedlack; Jonathan Katz; Richard Barohn; Eric Sorenson; Bjorn Oskarsson; Americo Fernandes Filho; Edward Kasarskis; Tahseen Mozaffar; Sharon Nations; Andrea Swenson; Agnes Koczon-Jaremko; Georgia Christodoulou; Hiroshi Mitsumoto Journal: Behav Neurol Date: 2018-10-31 Impact factor: 3.342
Authors: Claire J Lansdall; Ian T S Coyle-Gilchrist; Patricia Vázquez Rodríguez; Alicia Wilcox; Eileen Wehmann; Trevor W Robbins; James B Rowe Journal: Neurology Date: 2019-03-06 Impact factor: 9.910
Authors: Chern Yi Marybeth Chang; Waqaar Baber; Tom Dening; Jennifer Yates Journal: Int J Environ Res Public Health Date: 2021-06-11 Impact factor: 3.390
Authors: Rosanne Govaarts; Emma Beeldman; Mike J Kampelmacher; Marie-Jose van Tol; Leonard H van den Berg; Anneke J van der Kooi; Peter J Wijkstra; Marianne Zijnen-Suyker; Nicolle A M Cobben; Ben A Schmand; Rob J de Haan; Marianne de Visser; Joost Raaphorst Journal: J Neurol Date: 2016-09-26 Impact factor: 4.849